RxDoctor Payments Data

David Wiggans, MD

Internal Medicine · Dallas, TXNPI 1750368155

Payments from drug & device makers

$388in general payments, 2019–2025

Across 22 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$88
  • Abbott$67
  • Astellas Pharma US Inc$41
  • Sanofi Pasteur Inc.$37
  • Lilly USA, LLC$35
  • Pfizer$29
  • plus $91 from 6 others

What the payments were for

  • Food & beverage$388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK5$88
Abbott3$67
Astellas Pharma US Inc2$41
Sanofi Pasteur Inc.2$37
Lilly USA, LLC2$35
Pfizer2$29
AbbVie1$17
Metuchen Pharmaceuticals1$17
AstraZeneca1$16
Exact Sciences1$15
Shire North American Group Inc1$14
Merck1$12

How this compares

$388 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$48,524
Medicare patients
250
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$15,118
SynthroidLevothyroxine Sodium30$2,549
Atorvastatin Calcium220$2,043
Levothyroxine Sodium156$1,684
Rosuvastatin Calcium121$1,600
Metoprolol Succinate54$1,463
Amlodipine Besylate183$1,401
Lisinopril127$1,092
Losartan Potassium109$957
Pravastatin Sodium37$602
Sertraline Hcl60$569
Potassium Chloride18$554
Pantoprazole Sodium33$517
Allopurinol45$478
Hydrochlorothiazide72$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$15,11813 claims
AbbVieSynthroid$17$2,54930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →